There is an alarming increase of medicinal products detected in the Union which are falsified in relation to their identity, history or source. Those products usually contain sub-standard or falsified ingredients, or no ingredients or ingredients, including active substances, in the wrong dosage thus posing an important threat to public health.
Recital 2, Directive (EU) 2011/62
Judgment of the Court (Fifth Chamber) of 17 November 2022. Merck Sharp & Dohme BV and Others v Abacus Medicine A/S and Others.Decision
Recitals 2, 3, 11, 12, 29 and 33 of Directive 2011/62/EU of the European Parliament and of the Council of 8 June 2011 amending Directive 2001/83 (OJ 2011 L 174, p. 74) state: There is an alarming increase of medicinal products detected in …
17 Nov 2022 · 62020CJ0224
Opinion of Advocate General Szpunar delivered on 18 December 2025. FARMAKEIO YZ & SIA O.E. v Ypourgos Anaptyxis kai Ependyseon and Ypourgos Decision
In the second place, the same applies to the justification concerning the strengthening of the security of supply chains of medicinal products in order to prevent the placing on the market of medicinal products containing sub-standard or …
18 Dec 2025 · 62024CC0604
Judgment of the Court (Fifth Chamber) of 17 November 2022. Bayer Intellectual Property GmbH v kohlpharma GmbH.Decision
Recitals 2, 3, 11, 12, 29 and 33 of Directive 2011/62/EU of the European Parliament and of the Council of 8 June 2011 amending Directive 2001/83 (OJ 2011 L 174, p. 74) state: There is an alarming increase of medicinal products detected in …
17 Nov 2022 · 62020CJ0204
Judgment of the Court (Fifth Chamber) of 17 November 2022. Novartis Pharma GmbH v Abacus Medicine A/S.Decision
Recitals 2, 3, 11, 12, 29 and 33 of Directive 2011/62/EU of the European Parliament and of the Council of 8 June 2011 amending Directive 2001/83 (OJ 2011 L 174, p. 74) state: There is an alarming increase of medicinal products detected in …
17 Nov 2022 · 62020CJ0147